4 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 4, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow Fulvestrant: new trials by email Literature Review of Fulvestrant trials Research Report on Fulvestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment Alpelisib, Fulvestrant - Advanced Breast Cancer | Phase 4 | Completed | Novartis Pharmaceuticals | 40 | 2022-08-09 | 2026-07-09 |
| Roll-over Study to Allow Continued Access to Ribociclib Ribociclib, Letrozole, Anastrozole - Metastatic Breast Cancer | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 134 | 2022-07-07 | 2026-10-19 |
| Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant - Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer | Phase 4 | Recruiting | Prof. Wolfgang Janni | 300 | 2022-04-27 | 2025-05-16 |
| A Study of Abemaciclib in Indian Women With Advanced Breast Cancer Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI), Fulvestrant - Breast Neoplasms, Neoplasm Metastasis | Phase 4 | Completed | Eli Lilly and Company | 200 | 2021-02-22 | 2023-11-24 |
| A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer Abemaciclib, Fulvestrant, Standard Chemotherapy - Metastatic Breast Cancer | Phase 4 | Terminated | Eli Lilly and Company | 4 | 2019-08-14 | 2021-08-24 |
| Fulvestrant in Metastatic Breast Cancer Faslodex, Zoladex - Metastatic Breast Cancer | Phase 4 | Unknown | Assiut University | 30 | 2018-08-01 | 2018-07-23 |
| A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) - Metastatic Breast Cancer | Phase 4 | Completed | GBG Forschungs GmbH | 130 | 2018-03-01 | 2024-10-01 |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy Palbociclib, Fulvestrant, Anastrozole - Breast Neoplasm | Phase 4 | Terminated | Palleos Healthcare GmbH | 532 | 2017-07-24 | 2022-01-06 |
| A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Fulvestrant - Locally Advanced or, Metastatic Breast Cancer | Phase 4 | Completed | AstraZeneca | 83 | 2015-05-29 | 2021-09-05 |
Breast Neoplasms (8) · Neoplasm Metastasis (2) · Multiple Endocrine Neoplasia Type 1 (1) · Patient Acceptance of Health Care (1)
Eli Lilly and Company (2) · Novartis Pharmaceuticals (2) · Assiut University (1) · AstraZeneca (1) · GBG Forschungs GmbH (1) · Palleos Healthcare GmbH (1) · Prof. Wolfgang Janni (1)
Germany (3) · India (3) · South Korea (2) · United States (2) · Argentina (1) · Brazil (1) · China (1) · Costa Rica (1) · Greece (1) · Hong Kong (1) · Italy (1) · Japan (1) · Lebanon (1) · Mexico (1) · Peru (1)
Brigitte Rack, Prof. Dr. (1) · Iris Reiser, PhD (1) · Sibylle Loibl, MD, PhD (1)
2016 (1)